Cargando…

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours

AIM: Develop a population pharmacokinetic (PopPK) model to characterise the pharmacokinetics (PK) of anti‐programmed cell death protein‐1 (PD‐1) antibody dostarlimab, identify covariates of clinical relevance, and investigate efficacy/safety exposure–response (ER) relationships. METHODS: A PopPK mod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melhem, Murad, Hanze, Eva, Lu, Sharon, Alskär, Oskar, Visser, Sandra, Gandhi, Yash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543385/ https://www.ncbi.nlm.nih.gov/pubmed/35357027 http://dx.doi.org/10.1111/bcp.15339

Ejemplares similares

Comparative analysis of PD‐1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL‐2 stimulation data
por: Austin, Daren, et al.
Publicado: (2022)

An Integrated Analysis of Dostarlimab Immunogenicity
por: Lu, Sharon, et al.
Publicado: (2021)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
por: Patnaik, Amita, et al.
Publicado: (2021)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Dostarlimab/tozinameran: Various toxicities: case report
Publicado: (2022)

Dostarlimab: The miracle drug for the treatment of colorectal cancer
por: Shuvo, Pollob Ahmed, et al.
Publicado: (2022)

Jemperli (Dostarlimab-gxly): An unprecedented cancer trial
por: Ali, Eman, et al.
Publicado: (2022)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
por: André, Thierry, et al.
Publicado: (2023)

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
por: Singh, Vanshikha, et al.
Publicado: (2022)

Dostarlimab, a boon or a healthcare burden- too early to acertain!
por: Fatima, Nabeela, et al.
Publicado: (2022)

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
por: Oaknin, Ana, et al.
Publicado: (2020)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
por: Alkholifi, Faisal K., et al.
Publicado: (2022)

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
Publicado: (2022)

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake
por: Keunecke, Anne, et al.
Publicado: (2020)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023)

Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021)

Model‐Based Interspecies Scaling of Glucose Homeostasis
por: Alskär, Oskar, et al.
Publicado: (2017)

Pharmacokinetics of Monoclonal Antibodies
por: Ryman, Josiah T., et al.
Publicado: (2017)

On the monoclonality of tumours.
por: Baverstock, K. F.
Publicado: (1986)

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
por: Yap, Timothy A, et al.
Publicado: (2022)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
por: Oaknin, Ana, et al.
Publicado: (2023)

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours
por: Price, T J, et al.
Publicado: (2008)

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet
por: Chen, Ping, et al.
Publicado: (2019)

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.
por: Desoize, B., et al.
Publicado: (1990)

High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.
por: Bisogno, G., et al.
Publicado: (1998)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
por: Jeong, Tae-Jun, et al.
Publicado: (2022)

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models
por: Kumar, Sujatha, et al.
Publicado: (2021)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
por: Faessel, Hélène, et al.
Publicado: (2019)

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
por: Madariaga, Ainhoa, et al.
Publicado: (2023)

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours
por: Ahlskog, J K J, et al.
Publicado: (2009)

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_3f3l1km62rqoa2il702tfvea8o